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Introduction {#sec001}
============

Adoptive therapy using tumour-specific T-cells can be a very effective treatment for human cancer, but naturally occurring T-cells with the appropriate tumour specificity are rare. Therefore more recent work has employed genetic engineering techniques to rapidly and reliably introduce genes encoding receptors specific for defined tumour antigens\[[@pone.0224015.ref001]\]. This includes engineering T-cells to induce expression of a chimeric antigen receptor (CAR), which generally combines the antigen-binding domains of an antibody in the form of a single chain variable fragment (scFv) linked to the signalling domain (CD3ζ chain) from the T-cell receptor complex. Such CARs based on an antibody specific for the B cell marker CD19 have proven highly effective in treating some leukaemias\[[@pone.0224015.ref002]--[@pone.0224015.ref004]\], leading to recent FDA approval for some of these therapies. Unsurprisingly, these CD19-specific CARs mediate so called "on-target, off-tumour" effects since the target antigen is also expressed on healthy B cells leading to B-cell aplasia and hypogammaglobulinaemia, but this can be managed clinically by regular infusions with immunoglobulin.

Given the clinical success of CAR T-cell therapy for leukaemias, there is considerable interest in extending its use to the more common solid tumours. However, this is proving more challenging, partly because of the hostile tumour microenvironment that can include multiple immune evasion mechanisms but also because of the lack of suitable target antigens. Targeting the tumour stroma such as the tumour vasculature, rather than the malignant cells directly, is an attractive alternative approach since it is readily accessed by circulating T-cells and is less genetically unstable than malignant cells\[[@pone.0224015.ref005]\], reducing the likelihood of antigen-loss variants\[[@pone.0224015.ref006]\]. Furthermore, targeting the tumour vasculature should not only damage the surrounding tumour tissue but also malignant tissue downstream of that vessel. This approach again requires the identification of specific antigens, and a growing list of tumour endothelial markers (TEMs) have been described.

TEM8 was originally identified as a TEM in colorectal carcinoma\[[@pone.0224015.ref007]\] and although it is expressed in the endothelial cells of developing mouse embryos\[[@pone.0224015.ref008]\], it was not detectable in healthy tissues of adult mice\[[@pone.0224015.ref009]\]. Equally, studies in human tissues failed to detect it during physiological angiogenesis required for corpus luteum development and wound healing\[[@pone.0224015.ref007]\]. TEM8 is a single-pass cell surface glycoprotein 564 amino acids long, with a von Willebrand factor type A (vWA) domain in its extracellular region\[[@pone.0224015.ref010]\]. It is highly conserved with 96% amino acid sequence identity between mouse and man\[[@pone.0224015.ref008]\]. TEM8 binds collagen and promotes endothelial cell migration in vitro and is thereby thought to play an important role in angiogenesis\[[@pone.0224015.ref011], [@pone.0224015.ref012]\]. TEM8 also acts as a receptor for anthrax toxin\[[@pone.0224015.ref013]\], and is known as anthrax toxin receptor 1 (ANTXR1).

In addition to colorectal cancer, TEM8 is upregulated on vessels in various human and mouse tumour types\[[@pone.0224015.ref008], [@pone.0224015.ref011], [@pone.0224015.ref014]\], and in some cases is also expressed by the malignant cells\[[@pone.0224015.ref008], [@pone.0224015.ref015], [@pone.0224015.ref016]\]. Its importance in cancer has been demonstrated using TEM8 knockout mice that show impaired tumour growth\[[@pone.0224015.ref009], [@pone.0224015.ref017]\]. Furthermore, targeting this molecule in mice using TEM8 vaccines\[[@pone.0224015.ref018], [@pone.0224015.ref019]\], an anti-TEM8/truncated tissue factor fusion protein\[[@pone.0224015.ref014]\] and sublethal doses of anthrax toxin\[[@pone.0224015.ref020]\] can inhibit angiogenesis and tumour growth, as well as prolong survival. In 2012, a study using antibody phage display reported the generation of five TEM8-specific human antibodies (L1, L2, L3, L5 and 1D2) which inhibited tumour-induced angiogenesis as well as cancer growth in several mouse tumour models\[[@pone.0224015.ref009]\]. More recently, the safety and therapeutic potential of a TEM8-specific CAR based on the L2 antibody was explored using mouse models of triple negative breast cancer\[[@pone.0224015.ref021]\]. These studies showed that not only could infusion of these L2 CAR T-cells inhibit tumour growth, but there were no toxic effects reported.

Here we present contrasting findings using a panel of TEM8-specific CARs based on the same antibodies. Some of these, including L2, caused significant toxicity in healthy mice, apparently through targeting of TEM8 in healthy tissue, thus raising concerns over the use of such CARs for human studies.

Results {#sec002}
=======

Generation and expression of TEM8-specific CARs {#sec003}
-----------------------------------------------

The gene sequences encoding scFv domains based on the TEM8-specific human antibodies L1, L2, L3, L5 and 1D2 were cloned into retroviral vectors to encode second generation CARs with a CD28 costimulatory domain upstream of the CD3ζ chain as illustrated in [Fig 1A](#pone.0224015.g001){ref-type="fig"}. In addition, the CAR gene was separated from a truncated CD34 marker gene by a foot-and-mouth disease virus 2A peptide linker, ensuring equimolar expression of both genes. In this way CD34 expression could be used as a marker for CAR expression. Following transduction of human T-cells using these retroviral vectors, the CD34 marker gene was clearly detectable by flow cytometry for all five CAR constructs, indicating that all five CARs are readily expressed ([Fig 1B](#pone.0224015.g001){ref-type="fig"}).

![Generation and expression of CAR constructs in T-cells.\
(A) Schematic representation of recombinant retroviral vectors encoding TEM8-specific CARs. Recombinant retroviral vectors coexpressed a truncated human CD34 marker and an scFv fragment from one of 5 different TEM8-specific monoclonal antibodies linked to a CD28 costimulatory domain and a CD3 zeta chain. The 2A peptide linker ensured equimolar expression of both gene constructs. (B) Expression of all 5 TEM8-specific CARs (based on monoclonal antibodies L1, L2, L3, L5 and 1D2) in T cells was demonstrated by flow cytometry staining for the coexpressed CD34 marker. % values show proportion of cells stained for CD34 in transduced T cells (black line) compared to mock-transduced T cells (shaded).](pone.0224015.g001){#pone.0224015.g001}

In vitro testing of TEM8-specific CAR T-cells {#sec004}
---------------------------------------------

To explore the function of human T-cells expressing the five different CARs, they were co-cultured with the LS174T tumour cell line which is naturally TEM8-negative\[[@pone.0224015.ref009]\] but which we engineered to stably express the mouse form of TEM8 ([S1 Fig](#pone.0224015.s001){ref-type="supplementary-material"}). As shown in [Fig 2A](#pone.0224015.g002){ref-type="fig"}, when testing for secretion of interferon-gamma (IFN-gamma), T-cells expressing four out of the five CARs specifically responded to the TEM8-expressing LS174T cells, with the strongest responses seen with L1 and L2 CARs. The only CAR that failed to show a clear response was that based on the 1D2 antibody. Further studies explored the cytotoxic activity of the different CAR T-cells using the same target cells and showed a similar pattern of response, with the highest levels of cytotoxicity seen with L1, L2 and L3 CARs, but no specific cytotoxicity with the 1D2 CAR ([Fig 2B](#pone.0224015.g002){ref-type="fig"}). Using recombinant human and mouse TEM8 proteins, titration studies showed that the CAR T-cell response (measured by secretion of IFNγ) was strongest with L1 and L2 CARs, and somewhat weaker responses seen with L3 and L5 CARs. However, although the 1D2 CAR showed low but detectable responses to the human TEM8 protein when tested at higher concentrations, there was no detectable response to the mouse protein ([Fig 2C](#pone.0224015.g002){ref-type="fig"}). These results compare well with the binding affinities of these antibodies, since the affinities of L1, L2, L3 and L5 for human and mouse TEM8 are all within the range of 0.18--0.36nM. In contrast, the affinity of 1D2 for human TEM8 is only 7.6nM, and for mouse TEM8 it is 31.2nM, approximately 100 times lower than each of the other four antibodies\[[@pone.0224015.ref009]\]. Data demonstrating the expression and antigen-specific function of these CARs in mouse T-cells are shown in [S2 Fig](#pone.0224015.s002){ref-type="supplementary-material"}.

![CAR T cell responses to mouse and human TEM8.\
Human T cells engineered to express TEM8-specific CARs (L1, L2, L3, L5, 1D2) or mock-transduced T cell controls were tested for response to LS174T cells engineered to express full-length mouse TEM8. Antigen specific responses were detected using (A) IFN-gamma ELISA and (B) cytotoxicity assay (tested at effector:target (E:T) ratios of 10:1 and 5:1). (C) Responses to titrated concentrations of recombinant human and mouse TEM8 protein were assessed by IFN gamma release. In all cases CAR-T cell lines were diluted with mock T cells to equalise for transduction efficiency. Graphs show the mean of triplicate cultures (± standard deviation, SD) and are each representative of 3 experiments.](pone.0224015.g002){#pone.0224015.g002}

In vivo testing of TEM8-specific CAR T-cells {#sec005}
--------------------------------------------

Having demonstrated TEM8-specific function for four of the CARs, we then began a series of small toxicity studies in healthy mice. In the first experiment, C57BL/6 mice were treated with a single intravenous infusion of 20 million total T-cells derived from a congenic (CD45.1^+^) mouse strain with 55%, 64%, 40% or 55% of these cells expressing the L1, L2, L3 or L5 CARs respectively. Not only were mice monitored closely for signs of toxicity, but the persistence of the infused CAR T-cells was also monitored by serial tail bleeds using the CD34 marker as an indicator of CAR expression and CD45.1 as a marker of the infused T-cell population. After 24hrs, mice injected with the L2 and L3 CAR showed signs of toxicity with a hunched posture, piloerection and greatly reduced levels of activity which necessitated culling of the animals. The remaining mice treated with L1 and L5 CARs did not show such signs, but tail bleeds indicated that although more than half of the infused T-cells initially expressed the CAR, within 3 days post-infusion nearly all of the L1 and L5 CAR-expressing cells were no longer detectable in the circulation. In contrast, infused T-cells that did not express the CAR (i.e. CD34^-^ CD45.1^+^) were clearly detectable and represented 35--42% of the total circulating T-cell pool at 3 and 7 days post infusion. The selective loss of CAR-expressing T-cells continued until day 28 when the experiment was ended ([Fig 3A](#pone.0224015.g003){ref-type="fig"}).

![TEM8-specific CAR T cells are selectively lost from the circulation in healthy mice.\
(A) Mouse T cells engineered to express TEM8-specific CARs (L1, 55% transduced; L2, 64% transduced; L3, 40% transduced; L5, 55% transduced) or mock-transduced T cell controls were injected (20 million total T cells/mouse) into single healthy C57BL/6 mice and persistence measured by sequential tail bleeds. Note mice treated with L2 and L3 CARs are not shown as they had to be culled within 24hrs post treatment. (B) Mouse T cells engineered to express TEM8-specific CARs (L1, 81% transduced; L5, 70% transduced; 1D2, 84% transduced) or a control CAR (no scFv, 77% transduced) were injected (20 million total T cells/mouse) into healthy C57BL/6 mice (n = 2 per group) and persistence measured by sequential tail bleeds. (C) Human T cells engineered to express TEM8-specific CARs (L2, 21% transduced; 1D2, 25% transduced) or a control CAR (no scFv, 22% transduced) were injected (20 million total T cells/mouse) into healthy NSG mice (n = 3 per group) on 3 occasions (indicated with black arrowheads) and persistence measured by sequential tail bleeds. Note mice treated with L2 CARs are not shown as they had to be culled 24hrs post treatment. (D) Human T cells engineered to express TEM8-specific CARs (L2, 55.6% transduced) or a control CAR (no scFv, 63% transduced) were injected (20 million total T cells/mouse) into healthy NSG mice (n = 3 per group) and persistence measured by tail bleeds. Changes in body weight of these mice are shown in (E). Graphs A-D show CAR T cells (CD34^+^) as a percentage of the total infused T cell population. Results shown in B are the mean of duplicate values and results shown in C, D and E are the mean of triplicate values (± SD).](pone.0224015.g003){#pone.0224015.g003}

In the second in vivo experiment, congenic mouse T-cells expressing the L1 or L5 CARs were again tested in healthy C57BL/6 mice but this time we also tested the 1D2 CAR, and T-cells expressing a control CAR that lacked a scFv domain (no scFv) and therefore should not target an antigen. Mice were infused with 20 million total T-cells of which 81%, 70%, 84% and 77% expressed the L1, L5, 1D2 and no scFv CARs respectively. None of the mice showed signs of overt toxicity, but all mice treated with the L1 and L5 CARs again showed rapid and selective depletion of the CAR expressing T-cells such that these cells became almost undetectable from day 9 ([Fig 3B](#pone.0224015.g003){ref-type="fig"}). In contrast, T-cells infused into these L1 and L5-treated mice that did not express the CAR (i.e. CD34^-^ CD45.1^+^) were again clearly detectable and represented \>35% of the total circulating T-cell pool. Mice treated with T-cells expressing the no scFv control CAR showed an initial drop in the percentage of infused cells expressing this CAR, but this stabilised 4 days post-infusion and remained at \~50% for the next 17 days. 1D2 CAR T-cells were selectively depleted during the first week but then remained at \~20% for the rest of the experiment.

The third in vivo experiment used human T-cells injected into healthy immunocompromised NSG mice. Three mice received 20 million total T-cells of which 21% expressed the L2 CAR and again within 24hrs they all showed the same signs of toxicity seen in the first in vivo experiment, which necessitated culling of the animals. In contrast, mice (n = 3 per group) treated with 20 million total human T-cells expressing the 1D2 CAR or the no scFv CAR control showed no signs of toxicity even when infused again on day 5 and day 9 with the same cells. Note 1D2 and no scFv CARs were expressed on 25% and 22% of the infused T cells respectively. Tail bleed analysis again showed that the 1D2 CAR T-cells persisted in the circulation to the same extent as the no scFv control CAR ([Fig 3C](#pone.0224015.g003){ref-type="fig"}). The fourth in vivo experiment largely repeated the third although L2 and no scFv CARs were expressed on 56% and 63% of 20 million total infused T-cells respectively, and 1D2 CAR was not tested. Toxicity was again observed in all three L2 CAR-treated mice (hunched posture, piloerection and greatly reduced levels of activity) this time 3 days post infusion. In contrast, mice treated with the control (no scFv) CAR showed no toxicity. Three days post infusion, mice were analysed for persistence of infused cells and again there was clear evidence for selective loss of TEM8-specific CAR T-cells from the peripheral blood ([Fig 3D](#pone.0224015.g003){ref-type="fig"}). The L2 CAR-treated mice in this fourth in vivo experiment also showed a clear loss in body weight whereas no such change was seen in control (no scFv) CAR treated mice ([Fig 3E](#pone.0224015.g003){ref-type="fig"}). Three days post infusion all mice in this fourth experiment were culled and tissues taken for histological analysis. Haematoxylin and eosin stained sections were analysed by an experienced pathologist who was unaware of the treatment received by each mouse. Brain, colon, liver, kidney, pancreas, and heart tissues showed no pathology in either group of mice, but lung and spleen tissues showed evidence of inflammation in all L2 CAR treated animals, with numerous neutrophils present both in the red pulp of the spleen and surrounding the blood vessels and bronchioles in the lung. In contrast, there was no infiltration of neutrophils in the lung or spleen tissues of any mice treated with the control (no scFv) CAR ([Fig 4](#pone.0224015.g004){ref-type="fig"} and [S3 Fig](#pone.0224015.s003){ref-type="supplementary-material"}).

![Histological analysis of mice treated with TEM8-specific or control CAR T-cells.\
Representative images of haematoxylin and eosin stained lung and spleen tissues from the fourth in vivo experiment where NSG mice were treated with human T cells engineered to express TEM8-specific CARs (L2) or a control CAR (no scFv). Mice (n = 3 per group) were injected with 20 million total T cells/mouse of which 11.1 million and 12.6 million expressed the L2 and no scFv CARs respectively. Tissues were taken 3 days later and showed evidence of neutrophil infiltration in all L2 CAR treated mice but none of the control CAR treated mice. (Magnification = x400).](pone.0224015.g004){#pone.0224015.g004}

Finally, to explore whether these effects were dependent on TEM8 expression, we used a TEM8 knockout mouse. Mouse T-cells from a congenic strain were engineered to express the L2 TEM8-specific CAR or a control (no scFv) CAR and injected intravenously into healthy wild type and TEM8 knockout C57BL/6 mice. On this occasion, the L2 CAR T-cells did not mediate a toxic reaction even though the number of infused T-cells that expressed the CAR was similar to previous experiments. Nevertheless, these CAR T cells were again selectively lost from the circulation in wild type mice as had been observed with all the high affinity TEM8-specific CARs in the mouse experiments described above. Importantly, however, L2 CAR T-cells persisted in the circulation of TEM8 knockout mice. The control CAR T-cells persisted in the circulation of both mouse strains. Thus selective loss of L2 CARs from the circulation was TEM8-dependent ([Fig 5](#pone.0224015.g005){ref-type="fig"}).

![Persistence of TEM8-specific CAR T cells in the circulation of healthy wild type and TEM8 knockout mice.\
Mouse T cells from a congenic strain were engineered to express the L2 TEM8-specific CAR or a control CAR (no scFv) lacking the scFv antigen-binding domain. T cells were injected intravenously into wild type (black bars) or TEM8 knockout mice (white bars) and tail bleeds sampled to identify the infused cells (CD45.1^+^) that expressed the CAR (CD34^+^). Graphs show the results of two separate experiments where tail bleeds were analysed (A) 8 days and (B) 6 days post infusion. All experiments used two mice per group (except where indicated). T cells engineered for these experiments were \>50% transduced, and for data shown in (A) and (B) the number of infused T cells per mouse that actually expressed a CAR was 5 million and 12 million respectively. Data represent the mean percentage (+ SD) of infused cells that expressed a CAR.](pone.0224015.g005){#pone.0224015.g005}

Discussion {#sec006}
==========

Studying a panel of CARs specific for the tumour endothelial marker TEM8, we identified significant toxicity when some of them were tested in healthy mice. Furthermore, we also demonstrated selective and rapid depletion of all high avidity TEM8-specific CAR T-cells from the circulation. This suggested the CARs were targeting TEM8 or cross-reacting with another antigen expressed on healthy tissue(s) which resulted in toxicity and/or migration of the CAR T-cells out of the bloodstream and into the target tissue(s). Histological analysis of TEM8-specific CAR T-cell-treated mice also revealed evidence of inflammation in lung and spleen tissue. Studies using a TEM8 knockout mouse subsequently showed that selective loss of the CAR T-cells from the circulation was TEM8 dependent, strongly suggesting that the CAR T-cells are recognising TEM8 expressed on healthy tissue(s). Thus, despite elevated levels of TEM8 expression in tumour tissues, levels on healthy tissues can still be sufficient to be targeted by a potent agent such as a high avidity multivalent CAR T-cell.

This finding is particularly significant given a recent publication demonstrating safety and anti-tumour efficacy in a mouse model of triple negative breast cancer using a CAR based on the same L2 antibody that mediated toxicity in 7/11 wild type mice in our studies\[[@pone.0224015.ref021]\]. Reasons for these contradictory findings could lie in subtle changes in the design of the CAR. For example, different retroviral vectors may have led to different levels of CAR expression per cell. Also, the scFv domain in our study comprised the heavy chain antibody sequence followed by the light chain, whereas in the other study the genes encoding these antibody chains were in reverse order. Equally, the other study tested two versions of L2 CAR that included a costimulatory region from CD28 with or without an additional costimulatory domain from 4-1BB. Most of their in vivo studies focused on the second CAR and showed no toxicity using doses of up to 10 million cells (70% transduced). Nevertheless, no toxicity was reported when the CAR with the CD28 domain alone was injected intratumourally at a dose of 25 million cells/mouse. Whatever the reasons for the lack of toxicity in this other study, our results demonstrating toxicity with an L2 CAR even at doses of 4 million CAR-expressing T-cells per mouse, combined with evidence for TEM8-mediated selective loss of high avidity CAR T-cells from the circulation of healthy mice, highlights the risk of on-target, off-tumour effects should a TEM8-specific CAR, especially one based on the L2 antibody, be tested in patients. This is of particular concern if strategies are employed to enhance the anti-tumour effects of the CAR, for example through dose escalation or increasing the levels of CAR expression and/or function. In support of our findings, it should be noted that toxicity was also reported when the L2 antibody was used to engineer mouse T-cells to express a secretable bi-specific T-cell engager. This engager used a TEM8-specific scFv from the L2 antibody linked to a scFv recognizing CD3. Intravenous injection of 10 million of these T-cells resulted in death of 7/10 mice\[[@pone.0224015.ref022]\].

To reduce the risk of on-target, off-tumour toxicity with such CARs, one possibility is to use them in a combinatorial approach, where T-cells are engineered to express two distinct receptors, and activation is dependent on encountering both target antigens which are only co-expressed in tumour tissues\[[@pone.0224015.ref023], [@pone.0224015.ref024]\]. Use of RNA transfection of T-cells for transient expression of the CAR\[[@pone.0224015.ref025]\] or use of suicide gene strategies\[[@pone.0224015.ref026]\] can also limit the risks, or better still a "tunable" system where CAR expression levels can be regulated through administration of a drug\[[@pone.0224015.ref027]\]. Alternatively, reducing the affinity of the TEM8-specific CAR might permit discrimination between levels of the target antigen expressed at the tumour site and levels expressed in healthy tissues as has been shown for other CARs\[[@pone.0224015.ref028], [@pone.0224015.ref029]\]. In this regard it is interesting to note that although the 1D2 TEM8-specific antibody has a 100-fold lower affinity than L2 for mouse TEM8\[[@pone.0224015.ref009]\], and according to our data T-cells expressing a 1D2 CAR do not respond to the mouse protein, this antibody has intermediate affinity for human TEM8. Preclinical safety and efficacy testing of a 1D2 CAR in a mouse model would, however, require generation of a human TEM8 knockin.

Methods {#sec007}
=======

Generating human and mouse CAR T cells {#sec008}
--------------------------------------

The gene sequences encoding each of the TEM8-specific human antibodies L1, L2, L3, L5 and 1D2 were kindly provided by B. St Croix (National Cancer Institute, Frederick, MD) and used to design synthetic DNA sequences (GenScript) encoding an scFv region and then cloned into the CAR vector pMP71.tCD34.2A.CD19.IEVζ\[[@pone.0224015.ref030]\] as a ClaI, NotI fragment, replacing the CD19-specific scFv region. These vectors were originally constructed using the MP71 retroviral expression plasmid (a kind gift from C. Baum, Hannover) and co-expressed a truncated human CD34 marker gene\[[@pone.0224015.ref031]\]. The gene sequences of all new constructs were verified.

To generate recombinant retrovirus for transducing mouse T cells, Phoenix ecotropic packaging cells were transfected with the appropriate MP71 retroviral expression vector encoding the CAR and pCL eco (Imgenex) using FuGENE HD (Roche) according to the manufacturer\'s instructions. Recombinant retrovirus for transducing human T cells was generated in the same way but using Phoenix amphotropic packaging cells and pCL ampho. Transduction of mouse T cells was conducted using mouse splenocytes pre-activated for 48 hours with concanavalin A (2μg/ml; Sigma) and mouse interleukin-7 (1ng/ml; eBioscience) in RPMI 1640 (Sigma) containing 10% foetal bovine serum (FBS; PAA, Pasching Austria), 2mM L-glutamine, 100 IU/ml penicillin, and 100ug/ml streptomycin (standard medium). For human T cells, peripheral blood mononuclear cells (PBMCs) were isolated from aphereses cones\[[@pone.0224015.ref032]\] collected from healthy adult volunteers (male or female, aged \>18 years) who attended the National Blood Donor Centre, Birmingham. PBMCs were isolated by density gradient centrifugation on Lymphoprep (Axis Shield, Oslo, Norway). They were then pre-activated for 48 hours using anti-CD3 antibody (30ng/ml; OKT3 eBioscience), anti-CD28 antibody (30ng/ml; 37407 R&D Systems) and interleukin-2 (IL2, 300 U/ml; Chiron, Emeryville, CA) in standard medium containing 1% human AB serum (TCS Biosciences, Buckingham, UK). Pre-activated human and mouse T cells were subsequently transduced (or mock-transduced with conditioned supernatant from non-transfected Phoenix cells) by spinfection in retronectin (Takara)-coated plates according to the manufacturer's instructions. After spinfection, mouse T cells were cultured for 24hrs in standard medium with IL2 (100 U/ml), then purified using Ficoll-Paque premium 1.084 (GE Healthcare). Human T cells were cultured in standard medium plus 1% human AB serum with IL2 (100 U/ml).

Cell lines {#sec009}
----------

LS174T cells\[[@pone.0224015.ref033]\] were obtained from ATCC and cultured in DMEM containing 10% FBS, 2mM L-glutamine, 100 IU/ml penicillin, and 100μg/mL streptomycin. Stable expression of mouse TEM8 within these cells was achieved by transduction using the lentiviral plasmids psPAX2 (lentiviral packaging; Addgene, Cambridge, MA, USA), pMD2G (envelope plasmid; Addgene) and pWPI lentiviral mammalian expression plasmid (Addgene) into which we had cloned the mouse TEM8 gene following digestion using PacI and PmeI restriction enzymes (New England BioLabs, MA). Plasmids were transfected into 293T cells (from ATCC) using FuGENE 6 according to the manufacturer\'s instructions in a ratio of 1:2.5:3.3 for pMD2G:psPAX2:pWPI. LS174T cells were then transduced with lentivirus-containing culture supernatant mixed with polybrene (8μg/ml, Merck, Millipore). Cell lines were screened for mycoplasma using MycoAlert detection kit (Lonza, Basel).

Recombinant TEM8 {#sec010}
----------------

Genes encoding the human or mouse forms of TEM8 fused to the human Fc protein were cloned into the pFUSE-mIgG2A-Fc1 vector (InvivoGen, San Diego, CA). TEM8 protein production was then carried out with the help of the Protein Expression Facility, University of Birmingham. Human TEM8-Fc/pFUSE-mIgG2A or mouse TEM8-Fc/pFUSE-mIgG2A plasmids were transfected into 293T cells using polyethylenimine (PEI 25000; Polysciences, Warrington, PA) in Opti-MEM Reduced Serum Medium (Gibco) and 7 days later supernatants were harvested and protein purified using Protein A Sepharose CL-4B (GE Healthcare) according to the manufacturer\'s instructions.

IFNγ ELISA {#sec011}
----------

LS174T cells (2x10^4^/well) were co-cultured in triplicate with human CAR T-cells (2x10^5^/well) in 96-well flat bottom plates. Alternatively CAR T-cells (2x10^5^/well) were incubated in wells pre-coated for 4 hours with recombinant TEM8-Fc protein (or Fc protein alone) at concentrations indicated. Cells were incubated at 37°C/5% CO~2~ in 100μl/well of RPMI supplemented with 10% FBS, 2mM L-glutamine, 100 IU/ml penicillin, and 100ug/ml streptomycin and IL2 (25 U/ml). After 18 hours, culture supernatant was tested for secreted IFN-gamma using an ELISA (Pierce Endogen, Rockford, IL) according to the manufacturer\'s instructions.

Cytotoxicity assay {#sec012}
------------------

Chromium release assays have been described in detail previously\[[@pone.0224015.ref034]\]. They were set up at known effector:target ratios (1250 targets/well) and harvested after 7.5 hours.

In vivo studies {#sec013}
---------------

Mice were housed in individually ventilated containers with a 12 hour day/night light cycle at temperatures of 21 +/- 2°C and relative humidity of 55% +/- 5%. All mice were allowed free access to water and a maintenance diet (EURodent diet 14%). All cages contained wood shavings, bedding material and a plastic house. Six to eight week old female C57BL/6 mice (Charles River Laboratories) or TEM8-knockout mice\[[@pone.0224015.ref017]\] (a kind gift from B. St Croix, National Cancer Institute, Frederick, MD) received non-myeloablative (5 Gy) total body irradiation (TBI) and 18 hours later CAR- or mock-transduced T-cells from CD45.1^+^ congenic BoyJ mice (Charles River Laboratories) were injected into the tail vein. Six to eight week old female NSG mice (Charles River Laboratories) were injected into the tail vein on up to 3 occasions with 20 million CAR- or mock-transduced human T-cells at the times and doses indicated. All mice were monitored every 15 minutes for the first hour post infusion, and then at least once daily for signs of toxicity. Humane endpoints included \>20% body weight loss, hunched posture, continued piloerection and/or inactivity for a period of 24hrs or dyspnoea. Once humane endpoints were reached they were culled immediately (note no animals died before meeting the humane endpoint criteria). Mice were assessed for toxicity by experienced animal workers and to avoid subjective bias they were blinded to the treatment group to which the animal had been assigned. Immune monitoring was conducted with serial tail bleeds. When staining T cells from heparinized tail bleeds they were first subjected to red blood cell lysis using BD Pharm Lyse (Becton Dickinson). They were then washed with PBS and stained with Live/Dead Fixable Violet Dead Cell Stain Kit (Life Technologies) for 20 mins in the dark, then washed with flow buffer (0.5% w/v BSA + 2mM EDTA in PBS; pH7.2). If staining for infused mouse T-cells, they were then stained with anti-mouse CD4-PE (clone H129.19), CD8-FITC (clone 53--6.7) and CD45.1-PE-Cy7 (clone A20) (all from BD Biosciences) for 30mins on ice in the dark. Alternatively when analysing infused human T-cells, they were stained with anti-human CD4-FITC (clone RPA-T4, BD Biosciences) and anti-human CD8-PE (clone RPA-T8, eBioscience). In all cases CAR-expressing cells were identified by co-staining with anti-human CD34-APC (clone 561, BioLegend). Cells were analysed using a BD LSR II flow cytometer and FlowJo software (TreeStar Inc, Ashland, OR). Histological analysis was conducted on formalin-fixed tissue stained with haematoxylin and eosin. Tissues were analysed using an Olympus SC100 microscope with Olympus cellSens Standard software.

Study approval {#sec014}
--------------

Studies with human donors were approved by the National Research Ethics Service Committee West Midlands (Solihull, UK). All donors were adults and gave written informed consent. All mouse studies were performed under UK Home Office authorisation and all animal workers were fully trained and held personal licenses granted by the UK Home Office.

Supporting information {#sec015}
======================

###### Mouse TEM8 expression in engineered LS174T cells.

LS174T cells transduced with a lentivirus expressing the murine form of TEM8 were stained with the TEM8 specific L2 monoclonal antibody (80ug/ml) or a concentration- and isotype-matched antibody control (clone ZX4, Thermo Fisher Scientific). They were then stained with a phycoerythrin-conjugated goat anti-mouse IgG antibody (Biorad) and analysed by flow cytometry using an LSRII Cytometer (Becton Dickinson) and FlowJo software (Tree Star).

(TIF)

###### 

Click here for additional data file.

###### CAR expression and function in engineered mouse T-cells.

\(A\) Expression of all 5 TEM8-specific CARs (L1, L2, L3, L5 and 1D2) and the no scFv control CAR in mouse T cells was demonstrated by flow cytometry staining for the coexpressed CD34 marker. % values show proportion of cells stained for CD34 in transduced T cells (black line) compared to mock-transduced T cells (shaded). (B) Antigen specific responses to LS174T cells expressing mouse TEM8 were detected using a mouse IFN-gamma ELISA platinum kit (Invitrogen). CAR-T cell lines were diluted with mock-transduced T cells to equalise for transduction efficiency. The graph shows the mean of duplicate cultures (± standard deviation, SD).

(TIF)

###### 

Click here for additional data file.

###### Representative images of haematoxylin and eosin stained tissues from the fourth in vivo experiment where NSG mice were treated with human T cells engineered to express TEM8-specific CARs (L2) or a control CAR (no scFv).

Mice (n = 3 per group) were injected with an effective dose of 11.1 million or 12.6 million T cells that all expressed the L2 or no scFv CAR respectively. Tissues were taken 3 days later. (Magnification = x200).

(TIF)

###### 

Click here for additional data file.

10.1371/journal.pone.0224015.r001
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\[EXSCINDED\]

PONE-D-19-17502

TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo

PLOS ONE

Dear Dr. Lee,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please make sure to address all comments by reviewers and make necessary changes.

We would appreciate receiving your revised manuscript by 9/21/19. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Nupur Gangopadhyay, B.V.Sc, M.V.Sc.,Ph.D.

Academic Editor

PLOS ONE

**Journal Requirements:**

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Thank you for stating the following in the Competing Interests section:

\"I have read the journal\'s policy and the authors of this manuscript have the following competing interests:  S.Lee is listed as an inventor on the following patent application/patent families; PCT/GB2017/050686 (published as WO2017/158337) and PCT/GB2017/050689 (WO2017/158339), and has interests in anti-CLEC14A CAR-T cells, studies relating to which have been supported by Cell and Gene Therapy Catapult UK and licensed to Chimeric Therapeutics Ltd\"

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

3.  We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Petrovic et al. describe a generally well done set of studies showing significant toxicity with CARs made with a series of anti-TEM8 antibodies. These data are in contrast to a recently published a paper in Cancer Research by the Baylor group that showed efficacy but no toxicity.

CAR behaviors can be very construct dependent, with slight changes making big differences. It is not entirely clear why the results of these two studies are different, but this is discussed in the discussion. However, I am very much in favor of publishing studies that show potential toxicity of CARs, as this needs to be taken into account when designing future clinical trials. The Baylor CAR may not be toxic, but certainly this paper provides data to suggest careful toxicity studies and a cautious clinical trial design are needed.

The validity of their findings is strengthened in my mind by NOT seeing toxicity in a Tem8 knockout mouse.

There are some critical omissions/clarifications that need to be addressed however.

1\. While transduction efficiency and killing assays are shown for the human CAR T cells in figs 1 and 2, no data is shown for the mouse CAR T cells. This is critical to provide, as mouse CAR T cells are difficult to make, and form a large part of the in vivo data.

2\. It would also be important to show the expression levels of Tem8 on the LS174T tumor cells. Were these cells sorted?

3\. Related to this- the authors must clarify an important point: In their animal experiments they state that they injected "20 million congenic mouse T cells expressing the CAR". Does this mean they inject 20 million total T cells or that they injected 20 million CAR expressing T cells? Here is where the transduction efficiency is so important. If they injected 20 million CAR expressing T cells, depending on the transduction efficiency, this could be a very large number of cells (i.e. a 50% transduction efficiency would mean injection of 40 million T cells). We usually do not inject greater than \~20 million total T cells.

4\. There was no histology data provided to give any clue about why the mice got so sick after injections. It can be hard to tell why a mouse died, but the paper would be strengthened by this data. Was there inflammation in the lungs, heart, liver, kidney, etc? Was there widespread vasculitis?

Reviewer \#2: Summary:

This paper presents contrasting data in terms of toxicity with TEM8-specific CARs to that which has been previously published. They show development of 5 different TEM8 CAR T cell variants generated from human L1, L2, L3, L5, and ID2 antibodies and their expression and specific cytotoxicity efficacy in vitro via INFγ secretion and chromium release cytotoxicity studies with appropriate controls. ID2 was the only CAR T cell that did not have specific cytotoxicity. They then performed in vivo experiments for persistence by injecting these CAR T cells into healthy immunocompetent mice and performing serial blood draws. The mice injected with L2 and L3 TEM8 CAR T cells had severe toxicity. While the L1 and L5 variants did not have toxicity the cells did not persist long. Finally they demonstrate that the failure to persist is most likely related to recognition of TEM8 on healthy tissue as persistence is of these cells is demonstrated in the TEM8 knockout mice.

Comments:

• The n for mouse studies is small with only 2-3 mice per group, however, results are consistent between the mice in each study

• The timing of the blood draws for CAR T cell persistence is very variable between experiments and it is not clear why this is the case. The initial experiment was done with blood draws on day 3, 7, and 28. The second experiment looks like day 4, 9, 15, and 21. Then day 3 for the human T-cell experiment which was when these mice needed to be culled. Finally in the knockout mice blood draws happened day 8 for one experiment and day 6 for the other experiment. It is just very inconsistent

• In addition, in the last mouse experiment with the TEM8 knockout mice, the authors comment on the fact that the L2 scFv did not mediate a toxic reaction in this experiment but they also used only 5 million CAR T-cells compared to 20 million all prior experiments with similar transduction rates. I think this should be stated more clearly in the text and not just in the figure legend. The should also justify why they changed the dosing

• The figures could also have some tighter formatting in terms of size balance and labels. Specifically, for Figure 3 it would be helpful to label in the figure which graphs are done with mouse T-cells and which with human T-cells. In Figure 4, a legend showing what the bars represent rather than just stating it in the figure legend text

• Additionally, there are some minor grammatical errors and areas were the wording could be tightened up a bit -- specifically in the intro.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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20 Sep 2019

Dear Dr Gangopadhyay

Re. Manuscript PONE-D-19-17502 ("TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo").

Thank you for allowing us to submit a revised version of our manuscript and our thanks also to the reviewers for their comments. Each of the points raised by the reviewers is addressed below.

Reviewer \#1

1\. While transduction efficiency and killing assays are shown for the human CAR T cells in figs 1 and 2, no data is shown for the mouse CAR T cells. This is critical to provide, as mouse CAR T cells are difficult to make, and form a large part of the in vivo data.

We have included in a supplementary figure (fig S2) data demonstrating efficient transduction of mouse T-cells with our TEM8-specific CARs. This figure also includes data demonstrating that these cells are functional since they released IFNg in response to target cells expressing TEM8 (the same type of assay that we used in figure 3 when testing the function of human T-cells expressing these CARs).

2\. It would also be important to show the expression levels of Tem8 on the LS174T tumor cells. Were these cells sorted?

In another supplementary figure (fig S1) we have included flow cytometric data demonstrating expression levels of TEM8 in the engineered LS174T cells. The cells were not sorted.

3\. Related to this- the authors must clarify an important point: In their animal experiments they state that they injected "20 million congenic mouse T cells expressing the CAR". Does this mean they inject 20 million total T cells or that they injected 20 million CAR expressing T cells? Here is where the transduction efficiency is so important. If they injected 20 million CAR expressing T cells, depending on the transduction efficiency, this could be a very large number of cells (i.e. a 50% transduction efficiency would mean injection of 40 million T cells). We usually do not inject greater than \~20 million total T cells.

The total number of T-cells injected into a mouse did not exceed 20 million, and the proportion of these that expressed the CAR is indicated by the transduction efficiency stated. Nevertheless, to avoid any confusion, we have altered the text in the manuscript and figure legends to clarify this point.

4\. There was no histology data provided to give any clue about why the mice got so sick after injections. It can be hard to tell why a mouse died, but the paper would be strengthened by this data. Was there inflammation in the lungs, heart, liver, kidney, etc? Was there widespread vasculitis?

We have added a new figure (fig 4) and supplementary figure (fig S3) showing H&E stained sections from major organs taken from mice treated with the L2 CAR T-cells (or a no scFv control CAR). These were tissues taken from mice tested in the fourth in vivo experiment from which we also showed data in fig 3D-E). Interestingly these tissues indicate evidence of inflammation in the lungs and spleen of all 3 CAR treated mice since they contained infiltrating neutrophils. No such infiltration was detectable in the control (no scFv CAR treated mice) or in any other tissues studied.

Reviewer \#2

1\. The n for mouse studies is small with only 2-3 mice per group, however, results are consistent between the mice in each study

We agree the number of mice in each experiment was small but, as stated by this reviewer, the consistency of our findings between experiments supports the conclusions.

2\. The timing of the blood draws for CAR T cell persistence is very variable between experiments and it is not clear why this is the case. The initial experiment was done with blood draws on day 3, 7, and 28. The second experiment looks like day 4, 9, 15, and 21. Then day 3 for the human T-cell experiment which was when these mice needed to be culled. Finally in the knockout mice blood draws happened day 8 for one experiment and day 6 for the other experiment. It is just very inconsistent

Again we agree that the timings varied for the different experiments and this was largely due to logistical constraints on when we were able to take the blood samples. Nevertheless, the results demonstrate a consistent pattern of depletion of TEM8-specific CAR T-cells in wildtype mice from the circulation.

3\. In addition, in the last mouse experiment with the TEM8 knockout mice, the authors comment on the fact that the L2 scFv did not mediate a toxic reaction in this experiment but they also used only 5 million CAR T-cells compared to 20 million all prior experiments with similar transduction rates. I think this should be stated more clearly in the text and not just in the figure legend. The should also justify why they changed the dosing

The text in our original manuscript has confused Reviewer \#2 since these mice were infused with 5 million or 12 million CAR-expressing T-cells (not total T-cells). The potential for confusion in this area was also mentioned by Reviewer \#1 (point 3 above) and so we have modified the text throughout the manuscript to ensure clarity. Therefore the dose of CAR expressing T-cells infused in these experiments was not reduced, but was within the range of doses used in the earlier experiments. Again we have altered the text to make this point clear.

4\. The figures could also have some tighter formatting in terms of size balance and labels. Specifically, for Figure 3 it would be helpful to label in the figure which graphs are done with mouse T-cells and which with human T-cells. In Figure 4, a legend showing what the bars represent rather than just stating it in the figure legend text

We have altered these figures as requested.

5\. Additionally, there are some minor grammatical errors and areas were the wording could be tightened up a bit -- specifically in the intro.

We have attempted to improve the text to remove such errors but without more detail we are unable to deduce which parts of the text the referee is referring to.

We would like to thank the reviewers for their comments which we believe has strengthened the manuscript, and trust the revised version is now acceptable for publication.

Yours sincerely,

Steven P. Lee Ph.D.

Senior Research Fellow

###### 

Submitted filename: Response to referees.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0224015.r003
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TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo

PONE-D-19-17502R1

Dear Dr. Lee,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Nupur Gangopadhyay, B.V.Sc, M.V.Sc.,Ph.D.

Academic Editor

PLOS ONE
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TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo

Dear Dr. Lee:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr Nupur Gangopadhyay

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**S. Lee is listed as an inventor on the following patent application/patent families; PCT/GB2017/050686 (published as WO2017/158337) and PCT/GB2017/050689 (WO2017/158339), and has interests in anti-CLEC14A CAR-T cells, studies relating to which have been supported by Cell and Gene Therapy Catapult UK and licensed to Chimeric Therapeutics Ltd. Note this does not alter our adherence to PLOS ONE policies on sharing data and materials.

[^2]: Current address: Immunocore, Abingdon, Oxfordshire, United Kingdom.

[^3]: Current address: Achilles Therapeutics, Stevenage, Hertfordshire, United Kingdom.
